SCHEMBL29326623

SCHEMBL29326623

CCC(C)C(=O)CCCc1ccc(C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 1/20 0.44
PLAAT5 Q96KN8 1/20 0.44
PLAAT2 Q9NWW9 1/20 0.44
PLAAT4 Q9UL19 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SLC5A1 P13866 1/20 0.43
SLC5A2 P31639 1/20 0.43
TDP1 Q9NUW8 2/20 0.41
FFAR1 O14842 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
IGF1R P08069 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 2/20 0.40
CASP3 P42574 1/20 0.40
CASP7 P55210 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
NAAA Q02083 1/20 0.39
HPGD P15428 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10178819 0.85 SMN1; SMN2 (0.60) SMN1; SMN2TDP1CASP3HPGDALDH1A1
SCHEMBL22572494 0.84 PLAAT3 (0.48) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL11390257 0.76 TDP1 (0.55) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL21100446 0.76 ALDH1A1 (0.53) SMN1; SMN2FFAR1L3MBTL1HSD17B10ALDH1A1
SCHEMBL104964 0.76 ESR1 (0.49) SLC5A1SLC5A2TDP1HSD17B10HPGD
SCHEMBL5800604 0.75 TDP1 (0.50) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL23758082 0.75 GFER (0.43) L3MBTL1ALDH1A1
SCHEMBL105767 0.74 HSD17B10 (0.52) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL764952 0.74 SMN1; SMN2 (0.67) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL661277 0.74 PLAAT3 (0.51) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF FAP, FIBP, FGFR1 PLAAT3 128/4885PLAAT5 231/4885PLAAT2 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.